Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCC
A Single-Arm, Multicenter Phase Ib Study on the Efficacy and Safety of IBI310 in Combination With Bevacizumab and Sintilimab for First-Line Treatment of Advanced Hepatocellular Carcinoma
This is a single-arm, multicenter phase Ib study to evaluate the effectiveness and safety of IBI310, bevacizumab combined with sintilimab in patients with locally advanced or metastatic HCC who have not previously received systemic therapy, are unsuitable for radical surgical resection or local treatment, or have progressive disease after surgical resection or local treatment.
調査の概要
詳細な説明
This is a single-arm, multicenter phase Ib study evaluating the safety and efficacy of IBI310 combined with sintilimab and bevacizumab in advanced hepatocellular carcinoma. Patients will receive IBI310 1.0 mg/kg IV on day 1 every 6 weeks plus sintilimab 200 mg IV and bevacizumab 15 mg/kg IV on day 1 every 3 weeks. Approximately 50 patients are planned. After the first 6-10 patients are treated, the Safety Monitoring Committee (SMC) will assess safety in this subgroup and determine whether enrollment should continue.
Treatment will continue until disease progression, intolerable toxicity, initiation of new antitumor therapy, withdrawal of informed consent, loss to follow-up, death, or other protocol-defined discontinuation, whichever occurs first, for a maximum of 24 months. Patients with initial investigator-assessed radiographic progression per RECIST v1.1 may continue study treatment if clinically stable, likely to benefit, and willing to continue; tumor response will then be assessed by iRECIST until no further benefit per investigator, intolerable toxicity, new antitumor therapy, consent withdrawal, loss to follow-up, or maximum treatment duration, whichever occurs first.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Chengfeng Liu
- 電話番号:+86 15201927474
- メール:liu.chengfeng@zs-hospital.sh.cn
研究場所
-
-
-
Shanghai、中国
- 募集
- Zhongshan Hospital, Fudan University
-
コンタクト:
- Chengfeng Liu
- 電話番号:+86 15201927474
- メール:liu.chengfeng@zs-hospital.sh.cn
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologically/cytologically confirmed hepatocellular carcinoma, or meeting the clinical diagnostic criteria for hepatocellular carcinoma ;
- Aged ≥18 years,≤75 years;
- ECOG performance status score of 0 or 1 point;
- Barcelona Clinic Liver Cancer (BCLC) stage C, or Stage B not suitable for radical surgery and/or local treatment;
- No systemic antitumor treatment for hepatocellular carcinoma before the first administration;
- At least 1 measurable lesion according to the Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST V1.1), or measurable lesion with definite progression after local treatment (based on RECIST V1.1 criteria), at least 4 weeks before enrollment (for those who received local radioisotope therapy, at least 3 months)
- Child-Pugh Class A or B(≤7);
- Adequate organ and bone marrow function.
- Expected life time is over 12 weeks.
- Take effective contraceptive measures
- Willing to attend the study and having given the ICF
Exclusion Criteria:
- Known fibrolamellar HCC, sarcomatoid HCC, mixed cholangiocarcinoma and HCC
- History of hepatic encephalopathy or liver transplantation
- Pleural, ascites, and pericardial effusion with clinical symptoms requiring drainage
- HBV-DNA>2000 IU/ML or 10^4 copies/ml;Untreated positive HCV-RNA;HbsAg and anti-HCV antibody were both positive
- History of GI bleeding within 6 months, or severe (G3) varices at endoscopy within 3 months
- Arteriovenous embolism within 6 months
- The tumor thrombus involved both main and branch portal veins, main portal veins and mesenteric veins or inferior vena cava.
- Antiplatelet drugs were administered for 10 days for therapeutic purposes 2 weeks before administration
- Uncontrolled hypertension
- Unrecovered AE(>CTCAE grade 1) due to previous treatment
- Heart failure (NYHA Classification III-IV), or poorly controlled arrhythmias
- History of gastrointestinal perforation, fistula, intestinal obstruction, extensive bowel resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
- With lung fibrosis, interstitial lung disease, pneumoconiosis, drug-associated pneumonia and serious impairment in lung function
- Active tuberculosis
- Infected with HIV or syphilis
- Severe infections that are active or clinically poorly controlled
- Use of immunosuppressive drugs within 4 weeks prior to initial dosing
- Receipt of live attenuated vaccine within 4 weeks prior to randomization
- Significant traumatic injury or major surgical procedure within 28 days prior to randomization
- Other conditions that the investigator judged inappropriate for inclusion
- Prior immunotherapy or targeted therapy
- Treatment of Traditional Chinese medicine with anti-tumor indications or drugs with immunomodulatory effects whitin 2 weeks
- Pregnant or breast-feeding women
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Single-Arm
IBI310 1mg/kg IV d1 Q6W, sintilimab 200mg IV d1 Q3W, combined with bevacizumab 15mg/kg IV d1,Q3W |
IBI310 1mg/kg IV d1 Q6W sintilimab 200 mg IV d1 Q3W
他の名前:
bevacizumab 15 mg/kg IV d1,Q3W
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Treatment Emergent Adverse Event, TEAE
時間枠:Any emergent adverse event from first dose through study completion, up to 2 years.
|
Safety |
Any emergent adverse event from first dose through study completion, up to 2 years.
|
|
Severe Adverse Event, SAE
時間枠:Any severe adverse event from first dose through study completion, up to 2 years.
|
Safety |
Any severe adverse event from first dose through study completion, up to 2 years.
|
|
Objective response rate (ORR)
時間枠:The proportion of patients with complete response or partial response, through study completion, up to 2 years
|
efficacy |
The proportion of patients with complete response or partial response, through study completion, up to 2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Duration of Response(DOR)according to RECIST V1.1 criteria
時間枠:From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
|
efficacy |
From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
|
|
Duration of Response(DOR)according to mRECIST criteria
時間枠:From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
|
efficacy |
From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
|
|
Disease Control Rate(DCR) according to RECIST V1.1 criteria
時間枠:The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up to 2 years
|
efficacy |
The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up to 2 years
|
|
Disease Control Rate(DCR) according to mRECIST criteria
時間枠:The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up tp 2 years
|
efficacy |
The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up tp 2 years
|
|
Objective response rate (ORR) according to mRECIST criteria
時間枠:The proportion of patients with complete response or partial response, through study completion, an average of 2 years
|
efficacy |
The proportion of patients with complete response or partial response, through study completion, an average of 2 years
|
|
Progresison Free Survival(PFS)according to RECIST V1.1 criteria
時間枠:From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
|
efficacy |
From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
|
|
Progresison Free Survival(PFS)according to mRECIST criteria
時間枠:From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
|
efficacy |
From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
|
|
Overall survival (OS)
時間枠:From the date of randomization until death from any cause, assessed up to 48 months.
|
efficacy |
From the date of randomization until death from any cause, assessed up to 48 months.
|
協力者と研究者
捜査官
- 主任研究者:Zhenggang Ren、Shanghai Zhongshan Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CIBI310Y001
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。